Slide 1: Q3 2024 Business Update and Financial Results
Q3 2024 Business Update and Financial Results 13 November 2024
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: Conference call agenda
Q3 2024 Business Update and Financial Results Conference call agenda Strategic Overview and Outlook Jonathan Dickinson Chief Executive Officer, Chairman of the Executive Board Clinical Pipeline Progress Sonia Quaratino Chief Medical Officer ANKET®, ADC & monalizumab Yannis Morel Chief Operating Offi
Slide 4: Jonathan Dickinson appointed CEO of Innate Pharma
Jonathan Dickinson appointed CEO of Innate Pharma ▪ Experienced pharmaceutical and biotech executive ▪ Extensive experience gained working for Incyte Biosciences, ARIAD Pharmaceuticals, Bristol- Myers Squibb, Roche, Novartis, and Sandoz, “My purpose is rooted in transforming innovation into tangible
Slide 5: Strategic Overview and Outlook
Strategic Overview and Outlook Jonathan Dickinson Chief Executive Officer Chairman of the Executive Board 5
Slide 6: Scientific innovation drives our strategy
Scientific innovation drives our strategy Leveraging our expertise in innate immunity and antibody engineering to develop novel, first-in-class therapies for cancer, advancing a diverse pipeline of proprietary and partnered assets with major biopharma companies Lacutamab ANKET® & ADC Monalizumab Pha
Slide 7: Our robust pipeline of proprietary & partnered assets
Our robust pipeline of proprietary & partnered assets Pre-Clinical Phase 1 Phase 2 Phase 3 IPH67 IPH5301 (CD73) Lacutamab (KIR3DL2) Monalizumab (NKG2A) Undisclosed, solid tumor Solid tumors CTCL Unresectable Stg III NSCLC IPH81 IPH6501 (CD20-IL2v) Lacutamab (KIR3DL2) Undisclosed Target B-NHL PTCL Ot
Slide 8: Data across innovative oncology pipeline presented at SITC and ASH 2024
Data across innovative oncology pipeline presented at SITC and ASH 2024 ▪ Harnessing NK Cells in Cancer Therapies, Eric Vivier, CSO (Oral) ▪ Preclinical data supporting the evaluation of IPH6501 in relapsed or refractory B-NHL subtypes and post-CAR-T therapy (Poster) ▪ Preclinical data supporting IP
Slide 9: Pipeline Progress
Pipeline Progress Sonia Quaratino Chief Medical Officer 9
Slide 10: Proprietary key clinical pipeline progress
Proprietary key clinical pipeline progress Key clinical pipeline Lacutamab Phase 2 IPH6501 (CD20-IL2v) Phase 1 Phase 1 IPH4502 (Nectin-4) IND cleared Research
Slide 11: Lacutamab | Clinical Trials
Lacutamab | Clinical Trials A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 Cutaneous T cell lymphoma TELLOMAK Phase 2 Trial Sézary syndrome Sézary syndrome N=56 Phase 2 ~90% KIR3DL2 Minimum of 2 prior therapies, including mogamulizumab 2025 expression ≥1% Mycosis fungoid
Slide 12: TELLOMAK data support lacutamab as a potential new SoC in MF & SS
TELLOMAK data support lacutamab as a potential new SoC in MF & SS with opportunity across patient subgroups and earlier lines of therapy KIR3DL2 enriched population Expansion All comers Line Expansion ~ 1,500 patients ~3,500 patients ~5,000 patients KIR3DL2 KIR3DL2 All Comers All Comers <1% ≥ 1% ≥1
Slide 13: IPH6501, a novel CD20-targeting tetraspecific NK cell engager, has started clinical study
IPH6501, a novel CD20-targeting tetraspecific natural killer cell engager issued from ANKET® platform, has started clinical study in B-cell malignancies Phase 1/2 first-in-human, multicenter, in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma NCT06088654 First patient dosed in March 20
Slide 14: IPH6501 potential path forward
IPH6501 potential path forward Generate safety data and preliminary signals of activity in 2025 CD20+ B-NHL Confirm activity signal with dose optimized in CD20+ B-NHL 2026 & select B-NHL subtypes for expansion cohorts 2027 & Expansion study in selected B-NHL subtypes beyond & explore combination in
Slide 15: IPH4502 potential path forward
IPH4502 potential path forward 2024 IND cleared and generate preliminary Phase 1 safety data 2025 Establish preliminary activity signal in nectin-4 expressing tumor types 2026 with low and high expression levels Beyond Dose optimization and exploration of combination in expansion cohorts Data will i
Slide 16: ANKET®, ADC, monalizumab
ANKET®, ADC, monalizumab Yannis Morel Chief Operating Officer 16
Slide 17: Multiple ANKET® programs targeting hematological malignancies and solid tumors
Multiple ANKET® programs targeting hematological malignancies and solid tumors Growing clinical pipeline SAR’579 / IPH6101 (CD123) Phase 1 / 2 SAR443579 progress to Ph2 in R/R AML SAR’514 / IPH6401 (BCMA) Phase 1 / 2 New Phase 1/2 in 1L AML in combination with azacytidin + venetoclax IPH6501 (CD20-I
Slide 18: Data across innovative oncology pipeline presented at SITC 2024 Annual Meeting
Data across innovative oncology pipeline presented at SITC 2024 Annual Meeting ▪ Harnessing NK Cells in Cancer Therapies Eric Vivier, CSO (Oral) ▪ Preclinical data supporting the evaluation of IPH6501 in relapsed or refractory B-NHL subtypes and post-CAR-T therapy (Poster) ▪ Preclinical data support
Slide 19: Preclinical data support evaluation of IPH6501 in relapsed or refractory B-NHL subtypes
Preclinical data support evaluation of IPH6501 in relapsed or refractory B-NHL subtypes and post-CAR-T therapy NKp46 provides a key advantage for IPH6501 has potential across subtypes of B-NHL, IPH6501 over CD20-targeting Abs including in post CAR-T setting FL FL Killing by NK cells lymph node blood
Slide 20: IPH4502, a novel and differentiated exatecan-based ADC in Nectin-4 expressing tumors
IPH4502, a novel and differentiated exatecan-based ADC in Nectin-4 expressing tumors Nectin-4+ cells Nectin-4+ cells Nectin-4 KO cells + Nectin-4 KO cells Tumor volume (mm3) In vivo bystander killing Address heterogeneous Nectin-4 expression Efficacy in model of EV acquired resistance Address post-E
Slide 21: Monalizumab development in lung cancer
Monalizumab development in lung cancer Phase 2 NeoCOAST Phase 2 COAST Clinical Stg I-IIIA NSCLC Unresect. Stg III NSCLC monalizumab + durvalumab monalizumab + durvalumab studies in In progress In progress Phase 2 NeoCOAST-2 Phase 3 PACIFIC-9 NSCLC 999 pts Stg II-IIIA NSCLC Unresect. Stg III NSCLC Ar
Slide 22: Upcoming Catalysts and Closing Remarks
Upcoming Catalysts and Closing Remarks Arvind Sood President of US Operations 22
Slide 23: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts Delivering across our strategic objectives • Lacutamab TELLOMAK | Phase 2 FDA interaction • Lacutamab TELLOMAK | Next steps completed • Lacutamab PTCL | Phase 2 Data • IPH5301 (CD73) | Phase 1 data at ESMO 2024 Proprietary • IPH6501 ANKET® (CD20 IL2v) | Phase 1 progre
Slide 24: Key Takeaways
Key Takeaways Create value for patients and shareholders Clinical stage company with growing differentiated first-in-class pipeline • LACUTAMAB • Encouraging FDA feedback on regulatory pathway • EXPAND ANKET® CLINICAL PORTFOLIO – LEAD IN HEMATOLOGY INDICATIONS • Phase 1/2 clinical trial underway wit
Slide 25: Q&A
B innate pharma Q&A
Slide 26: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA